|
Hello, Thanks for signing up for MarketBeat Daily Ratings—we’re excited to have you on board. Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. You’re just two quick steps away from completing your sign-up: 1. Make sure our emails go to your inboxGmail users:
Mobile: Tap the three dots (…) in the top right and select Move to Inbox or Move to Primary
Desktop: Click the folder icon at the top and select Move to Inbox or Primary Apple Mail users:
Tap our email address at the top (next to From: on mobile), then select Add to VIP Other providers:
Reply to this message and add newsletters@analystratings.net to your contacts 2. Confirm your subscriptionClick this link to confirm your subscription. This verifies your account and ensures you receive your newsletters without interruption instead of getting stuck in your spam filter. Confirm your subscription here. After you confirm, feel free to download our popular free report, "7 Stocks to Buy and Hold Forever" with this link. Thanks again for subscribing—we look forward to being part of your investing journey. 
Matthew Paulson
Founder and CEO, MarketBeat. P.S. If you didn’t mean to subscribe, no problem—you can unsubscribe here.
Today's Exclusive Story
A Dividend King on Sale: Is Abbott Labs a Healthcare Bargain?Authored by Jeffrey Neal Johnson. Originally Published: 4/7/2026. 
Key Points
- Abbott's Medical Devices division continues to accelerate, demonstrating the underlying strength within the company's largest business segment.
- Abbott's impressive history of consecutive dividend increases underscores its commitment to consistently rewarding long-term shareholders.
- Strategic acquisitions are positioning Abbott to lead in new high-growth healthcare sectors, securing a powerful pipeline for future expansion.
- Special Report: Elon Musk already made me a “wealthy man”
In the world of investing, stability is a prized commodity. Few companies embody that stability better than Abbott Laboratories (NYSE: ABT), a diversified healthcare powerhouse and a member of the Dividend Kings. For decades, investors have relied on Abbott for steady growth and dependable income. That long-standing reputation makes its recent performance all the more striking.
A under-the-radar AI stock trading for just $3 could be one of the most overlooked opportunities in the market right now.
While Nvidia dominates headlines, this small-cap play is positioned for significant upside at a fraction of the price.
Discover our No. 1 AI pick before the broader market catches on. Reveal the $3 AI Pick
Abbott Laboratories’ stock price recently touched a 52-week low, closing just above $100 in the last trading days of March. The drop has left many wondering whether the foundation of this industry leader is cracking. A deeper look at Abbott’s situation reveals a potential disconnect between market sentiment and operational reality. The question for long-term investors is whether the pessimism is warranted, or whether a meaningful value opportunity has emerged. Separating the Signal From the NoiseA stock like Abbott does not decline without reason. The recent pullback reflects two distinct pressures. The first is an internal headwind from its Nutrition segment. Abbott’s fourth-quarter 2025 earnings report showed a 9.1% organic sales decline in this division, largely due to market-share losses in its U.S. pediatric business and pricing dynamics that constrained volume. Management has been transparent about the challenge and outlined a clear turnaround plan. CEO Robert B. Ford described pricing and promotion initiatives and a pipeline of at least eight new product launches in 2026 intended to reignite volume growth, with a forecasted return to growth in the second half of the year. The second factor is external and broader in scope: a market rotation of capital. In periods of economic optimism, investors often shift funds away from defensive sectors like the healthcare sector and into higher-beta areas such as artificial intelligence (AI) and the energy sector in search of faster returns. That broad trend has pressured many fundamentally sound healthcare names, including Abbott, for reasons largely unrelated to their individual performance or long-term prospects. Abbott’s Engine Room Is Running StrongWhile Nutrition navigates a short-term recovery, Abbott’s core remains exceptionally healthy, led by its largest and most profitable division: Medical Devices. That segment is not only stable but accelerating, posting 10.4% organic growth in the most recent quarter. Abbott’s diversified model helps offset the isolated weakness in Nutrition, and the company’s strength is clearest in its high-performing businesses.
Medical Devices: The Medical Devices engine is firing on multiple cylinders, driven by market-leading innovation in critical-care areas. Diabetes Care: The FreeStyle Libre franchise of continuous glucose monitors (CGM) remains a growth phenomenon. This product line, which lets users track glucose without routine fingersticks, generated over $7.5 billion in sales in 2025 and is a primary driver of Abbott’s sustained success. Cardiovascular Leadership: Abbott is a dominant force in cardiovascular health. Its Electrophysiology business grew at a double-digit rate, while Structural Heart posted strong organic growth of 8.7%. This strength stems from best-in-class products such as MitraClip and TriClip, which offer minimally invasive solutions for valve repair, and a pipeline that includes the recently FDA-approved Volt PFA System for treating atrial fibrillation. Abbott is also positioning for future growth through its acquisition of Exact Sciences. Exact Sciences is a leader in cancer screening and diagnostics, best known for Cologuard, a non-invasive colon cancer test. The deal would immediately expand Abbott’s addressable market into the rapidly growing, multi-billion-dollar cancer diagnostics space, adding a high-growth vertical that could meaningfully contribute to revenue over time. That bullish view is shared by many analysts. Wall Street maintains a Moderate Buy consensus on the stock, with an average 12-month price target of $135.47—implying more than 30% upside from current levels and suggesting the stock may be undervalued. A Bedrock of Reliability for Income InvestorsFor long-term, income-focused investors, Abbott’s dividend is a central attraction. Abbott is a member of the S&P 500 Dividend Kings—companies that have increased their dividend for at least 50 consecutive years. This rare track record underscores Abbott’s commitment to returning capital through all market cycles. The recent drop in Abbott’s stock price benefits new investors by boosting the dividend yield: at current prices, the yield is roughly 2.5%, allowing investors to lock in a higher income rate from a historically reliable payer. The dividend also appears secure. Abbott’s payout ratio is about 68% of earnings, and the dividend represents only about 37% of cash flow—indicating the company generates more than enough cash to cover distributions with room to grow them over time. A Disconnect Between Price and ValueCurrent market sentiment seems disconnected from Abbott’s business reality. Temporary headwinds in a single division and broader market rotations have weighed on the stock, yet Abbott’s fundamental growth engines are accelerating. Its dominant Medical Devices franchise continues to deliver, the dividend remains a dependable source of income, and strategic catalysts like the Exact Sciences acquisition could unlock new growth. For investors with a long-term horizon, the present valuation appears to reflect a meaningful gap between price and intrinsic value—an opportunity worth considering for those comfortable with a patient, income-oriented approach. |
